ライフサイエンスコーパス: cancer xenograft

1 GFR activation was also seen in a colorectal cancer xenograft.

2 HER3 overexpressing H441 non-small cell lung cancer xenograft.

3 ayed good in vivo efficacy in a human breast cancer xenograft.

4 r in the castration-recurrent human prostate cancer xenograft.

5 from the castration-recurrent CWR22 prostate cancer xenograft.

6 esicles inhibited patient-derived colorectal cancer xenograft.

7 e treatment on nude mice bearing HT-29 colon cancer xenograft.

8 aded with survivin siRNA, inhibited prostate cancer xenograft.

9 LIC4 in stromal cells enhances the growth of cancer xenografts.

10 high MET-expressing H441 non-small cell lung cancer xenografts.

11 bition in prodrug-treated mice bearing human cancer xenografts.

12 tive localization of phage to human prostate cancer xenografts.

13 ng A33 antigen-expressing, SW1222 colorectal cancer xenografts.

14 sis, and reduced tumor growth in established cancer xenografts.

15 xil(R) administration in A2780 human ovarian cancer xenografts.

16 utaneous syngeneic melanoma and human breast cancer xenografts.

17 cell compartment of primary human pancreatic cancer xenografts.

18 to exert antitumor effects against prostate cancer xenografts.

19 de were assessed in several human epithelial cancer xenografts.

20 nderexpressed in CD44(+) cells from prostate cancer xenografts.

21 ich vary during tumor growth in subcutaneous cancer xenografts.

22 estrogen-independent MDA-MB-231 human breast cancer xenografts.

23 ing the uterus or enhancing growth of breast cancer xenografts.

24 nitoring of VEGFR2 expression in human colon cancer xenografts.

25 sociated macrophages and the growth of colon cancer xenografts.

26 ion of sizable human lymphoma and pancreatic cancer xenografts.

27 y in androgen deprivation-resistant prostate cancer xenografts.

28 in SCID mice bearing MDA-MB231 human breast cancer xenografts.

29 in nude mice bearing CaPan1 human pancreatic cancer xenografts.

30 e bearing U87MG glioma and MDA-MB-435 breast cancer xenografts.

31 e collection of freshly generated pancreatic cancer xenografts.

32 as well as local invasion and metastasis of cancer xenografts.

33 ronously during the growth of human prostate cancer xenografts.

34 agent is confirmed using breast and prostate cancer xenografts.

35 ancer, ES-2 ovarian cancer and PC-3 prostate cancer xenografts.

36 n c-Met expression was confirmed in prostate cancer xenografts.

37 isense and enhanced CDDP-vinorelbine in lung cancer xenografts.

38 ed hormone-responsive tumor growth of breast cancer xenografts.

39 s a potent inhibitory signal in human breast cancer xenografts.

40 ously into mice bearing HBT3477 human breast cancer xenografts.

41 tate cancer cell lines and in human prostate cancer xenografts.

42 PAC in anesthetized nude mice bearing breast cancer xenografts.

43 reduces tumor growth in patient-derived lung cancer xenografts.

44 o in blood, and for DCE MR imaging of breast cancer xenografts.

45 rowth were also observed in mouse colorectal cancer xenografts.

46 major regressions of pancreatic and stomach cancer xenografts.

47 lung, and esophageal squamous cell carcinoma cancer xenografts.

48 in tumor pO2 in highly vascular 786-0 renal cancer xenografts.

49 cultured gastric cancer cells and in gastric cancer xenografts.

50 aring high EpCAM-expressing HT-29 colorectal cancer xenografts.

51 umumab, and injected into mice bearing colon cancer xenografts.

52 een chemotherapy cycles, using human bladder cancer xenografts.

53 opyruvate impaired the growth of endometrial cancer xenografts.

54 ncers and inhibited tumor outgrowth of basal cancer xenografts.

55 ction in tumor volumes in vivo in pancreatic cancer xenografts.

56 9 (colorectal cancer) and MDA-MB-231 (breast cancer) xenografts.

57 injection, P = 0.006) and the CWR22 prostate cancer xenografts (0.34 +/- 0.08 vs. 0.098 +/- 0.033 %ID

58 nd treatment-resistant HT29 human colorectal cancer xenografts 24 h after a single dose of conatumuma

59 nd treatment-resistant HT29 human colorectal cancer xenografts 24 h after a single dose of conatumuma

60 In cancer xenografts, (99m)Tc-TCP-1 radioactivity (%ID/g) w

61 d in three subtypes of orthotopic human lung cancer xenografts (A549, H460, and H520) in mice and in

62 tion, and in vivo growth of human pancreatic cancer xenografts after Bmi1 silencing.

63 iral vectors to target chk in a human breast cancer xenograft and noninvasive MRS detection of this t

64 tes was investigated in mice bearing ovarian cancer xenografts and compared to analogous radioimmunoc

65 ced tumor growth in both prostate and breast cancer xenografts and doubled the median survival time o

66 models using patient-derived LAPC-9 prostate cancer xenografts and established UM-UC-3 bladder tumors

67 ression and prolonged survival in pancreatic cancer xenografts and genetic mouse models.

68 triptase in vivo was measured in human colon cancer xenografts and in a patient-derived xenograft mod

69 ion of Duox expression in vivo in pancreatic cancer xenografts and in patients with chronic pancreati

70 an prostate epithelial cells, human prostate cancer xenografts and mouse prostate glands.

71 Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in

72 tenuated the growth of patient-derived colon cancer xenografts and reduced tumor blood flow.

73 The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy eff

74 restrained growth of desmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancer

75 tumor growth in mice bearing human prostate cancer xenografts, and heparin derivatives specifically

76 ce bearing androgen-dependent CWR22 prostate cancer xenografts, and male and female athymic nude mice

77 profoundly reduced growth of MM and ovarian cancer xenografts, and oral RA190 treatment retarded HPV

78 adiosensitizing agent against human prostate cancer xenografts, and that the mechanism may involve a

79 ureteral obstruction and metastasis of human cancer xenografts are suppressed by administration of se

80 ificantly slowed the growth of PC-3 prostate cancer xenografts as measured by size [75 +/- 35 versus

81 +/- 0.15, P < .001) of mice with esophageal cancer xenografts, as well as the smallest relative tumo

82 +/- 0.15, P < .001) of mice with esophageal cancer xenografts, as well as the smallest relative tumo

83 stablished HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectiv

84 ion with human PBMC, introduced into ovarian cancer xenograft-bearing mice, greatly exceeded the anal

85 [(18)F]-FLT-PET was conducted in human cancer xenograft-bearing mice.

86 (small, medium, large) in three subcutaneous cancer xenografts (breast, ovarian, pancreatic cancer) i

87 e accumulation in HER2-overexpressing breast cancer xenografts (BT-474).

88 ripheral blood of SCID mice bearing prostate cancer xenografts but not in tumor-bearing mice treated

89 r volume of tamoxifen-resistant MCF-7 breast cancer xenografts by 53%.

90 ce inhibited the growth of SW480 human colon cancer xenografts by 58% compared with control (P < 0.01

91 vestigation of EpoR expression in human lung cancer xenografts by fluorescence-mediated tomography.

92 el ((18)F-FPAC) in mice bearing human breast cancer xenografts by using small-animal-dedicated PET an

93 retomes in triple negative MDA-MB-231 breast cancer xenografts compared to ER-positive MCF-7 xenograf

94 iangiogenic treatment effects in human colon cancer xenografts compared with ex vivo reference standa

95 es in mice with breast, lung, and esophageal cancer xenografts consistently showed enhanced (89)Zr-AC

96 inistration of chemotherapy to human bladder cancer xenografts could trigger a wound-healing response

97 Prostate cancer xenografts derived from castration-resistant tumo

98 BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient wi

99 miRNAs originating from human prostate cancer xenografts enter the circulation, are readily mea

100 In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR

101 Human prostate cancer xenografts expressing high levels of human copper

102 nanoparticles accumulated in a human ovarian cancer xenograft following intravenous injection is demo

103 8 (HER2-negative/HER3-positive) human breast cancer xenografts from 4.4 +/- 0.9 to 2.6 +/- 0.5 %ID/g

104 (HER2-positive/HER3-negative) human ovarian cancer xenografts from 7.0 +/- 1.2 to 2.6 +/- 1.5 %ID/g

105 f palpable tumors in patient-derived ovarian cancer xenografts from ascites (PDXa).

106 SCID mice with human PC3 prostate cancer xenografts (Group IV, n=5) were also imaged with

107 restoration of NMI expression reduced breast cancer xenograft growth and downregulated Wnt and TGFbet

108 's potent suppression of A2780 human ovarian cancer xenograft growth in mice, it was the most potent

109 nd uterine enlargement and MCF-7 cell breast cancer xenograft growth in vivo were stimulated by estra

110 cancer cell proliferation and retards colon cancer xenograft growth.

111 Human non-small cell lung cancer xenografts (H460) in athymic rats were imaged wit

112 significantly inhibited the growth of human cancer xenografts harboring activated FGFR2 signaling.

113 ose per gram [%ID/g]) in BT-474 human breast cancer xenografts (HER2-positive/HER3-positive) occurred

114 biomarkers to identify radioresistant breast cancer xenografts highly amenable to sensitization by co

115 Different bladder cancer xenografts, however, demonstrate differential sen

116 In SKOV-3ip1 ovarian cancer xenografts, i.p. treatment with the c-Met siRNA s

117 siologic characteristics of a human prostate cancer xenograft implanted orthotopically in the prostat

118 vely blocks tumor growth in human pancreatic cancer xenografts in a nude mouse model.

119 gates gave high-contrast PET images of colon cancer xenografts in athymic mice.

120 f IGFBP-3R in vivo using prostate and breast cancer xenografts in athymic nude mice.

121 ble to assess tumor perfusion in human colon cancer xenografts in mice and allows for assessment of e

122 tive was to determine whether human prostate cancer xenografts in mice can be localized by PET using

123 It has shown activity against human ovarian cancer xenografts in mice rivaling that of cisplatin, bu

124 ) to VEGFR2 was tested in human LS174T colon cancer xenografts in mice with a 40-MHz ultrasonographic

125 ressed growth of the subcutaneous pancreatic cancer xenografts in mice with minimized side effects.

126 ivities (against human leukemia and prostate cancer xenografts in mice) of JS-K, a compound of struct

127 Using cell-based tests, orthotopic breast cancer xenografts in mice, and genome-wide transcription

128 t in vivo by inhibiting the growth of breast cancer xenografts in mice, which was associated with pro

129 tive NCI-N87 and HER2-negative MKN74 gastric cancer xenografts in mice.

130 rceptin) in HER2-overexpressing human breast cancer xenografts in mice.

131 particles) effectively targeted human breast cancer xenografts in mice.

132 the intestinal epithelium and in human colon cancer xenografts in mice.

133 t pitavastatin induces regression of ovarian cancer xenografts in mice.

134 icle as well as PLGA-PEG-NP into human colon cancer xenografts in mice.

135 monstrated that targeting of DU-145 prostate cancer xenografts in NMRI nu/nu mice was IGF-1R-specific

136 ibe a novel in vivo model using human breast cancer xenografts in NOD scid gamma (NSG) mice; in this

137 d androgen-dependent LuCaP 35 human prostate cancer xenografts in nude mice, castrated the mice, and

138 In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy

139 MBP-1 was given intratumorally in human lung cancer xenografts in nude mice.

140 ceptor kinase-expressing non-small cell lung cancer xenografts in rodents.

141 state cancer and the suppression of prostate cancer xenografts in SCID mice by forced expression of G

142 ed and selective activity against human lung cancer xenografts in vivo via the intravenous and oral r

143 Treatment of breast cancer xenografts in vivo with the retinoid fenretinide

144 l lines in vitro as well as in PC-3 prostate cancer xenografts in vivo.

145 he growth and proliferation rate of prostate cancer xenografts in vivo.

146 le growth inhibition and apoptosis in breast cancer xenografts in vivo.

147 of HER-2/neu-positive BT474-SC1 human breast cancer xenografts in vivo.

148 However, data from colorectal cancer xenografts indicated that (64)Cu-ATSM may not be

149 hRNA-mediated silencing of RON in pancreatic cancer xenografts inhibited their growth, primarily by i

150 of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF

151 delivery for VEGF knockdown in a human lung cancer xenograft, leading to enhanced tumour suppressive

152 Human prostate cancer xenografts (LNCaP) were transplanted subcutaneous

153 n of (18)F-F-CP in mice bearing human breast cancer xenografts (MCF-7 cells).

154 oliposomes in non-HER2-overexpressing breast cancer xenografts (MCF-7).

155 o anticancer activity against a human breast cancer xenograft (MDA-MB-435) in athymic nude mice.

156 Small-animal PET was performed in 3 human cancer xenograft mice models, expressing different level

157 In this breast cancer xenograft model (MDA-MB-436 cells), analysis of d

158 imary tumors and lung metastases in a breast cancer xenograft model as well as extravasation followin

159 tumor regression in the H146 small-cell lung cancer xenograft model at a well-tolerated dose schedule

160 election RNAi screening using a human breast cancer xenograft model at an orthotopic site in the mous

161 tion with temozolomide and in an MX-1 breast cancer xenograft model both as a single agent and in com

162 es performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzu

163 mor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as

164 aft results from the MDA-MB-468 human breast cancer xenograft model for compound 18 support the inves

165 y is shown with pretargeting in a pancreatic cancer xenograft model given a tri-Fab to a pancreatic c

166 ds in reducing tumorigenesis in a colorectal cancer xenograft model in athymic nude mice.

167 ith temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carbop

168 tient-derived CXCR7-expressing head and neck cancer xenograft model in nude mice, tumor growth was in

169 al drug-loaded micelles or free cisplatin in cancer xenograft model in vivo.

170 sis in vitro and in an orthotopic pancreatic cancer xenograft model in vivo.

171 duces cooperative antitumor activity in lung cancer xenograft model in vivo.

172 ce to 5-FU-induced apoptosis in a colorectal cancer xenograft model of 5-FU monotherapy.

173 In the nonsmall cell lung cancer xenograft model studied, a linear correlation bet

174 re, inducible knockdown of SCD1 in a bladder cancer xenograft model substantially inhibited tumor pro

175 s inhibit tumor growth in an N87 human colon cancer xenograft model via oral administration as shown

176 ivo during the progression of a human breast cancer xenograft model was guided by a bi-phasic host cy

177 In a human epithelial cancer xenograft model, Ad14P1 showed more efficient vir

178 romatase-transfected MCF-7 (MCF-7aro) breast cancer xenograft model, agreeing with our previous findi

179 In the CWR-22-BMSLD1 human prostate cancer xenograft model, BMS-641988 showed increased effi

180 one at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher

181 In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defe

182 nd negligible deleterious effects in a colon cancer xenograft model, giving rise to the possibility o

183 In a human breast cancer xenograft model, miR-221-overexpressing MDA-MB-23

184 uciferase-expressing ES-2 (ES-2-luc) ovarian cancer xenograft model, single i.p. injections of g-E an

185 In a human colon cancer xenograft model, the primary tumor was surrounded

186 ed tumor regression in the MDA-MB-231 breast cancer xenograft model.

187 , and inhibition of tumor growth in a breast cancer xenograft model.

188 ition effects using an MDA-MB-231/Luc breast cancer xenograft model.

189 trate this effect using a human PC3 prostate cancer xenograft model.

190 ted TFRC expression in a MYC-driven prostate cancer xenograft model.

191 -TOPK-032 suppressed tumor growth in a colon cancer xenograft model.

192 h when dosed orally in the MDA-MB-231 breast cancer xenograft model.

193 o and inhibition of tumor growth in a breast cancer xenograft model.

194 istered orally in a human BT474 human breast cancer xenograft model.

195 s tumor growth when dosed orally in a breast cancer xenograft model.

196 prolonged survival in the MDA-MB-231 breast cancer xenograft model.

197 n athymic nude mouse MDA-MB-231 human breast cancer xenograft model.

198 and activity in vivo in an SW620 colorectal cancer xenograft model.

199 obes (ChL6 is chimeric L6) in a human breast cancer xenograft model.

200 d a doxycycline (DOX)-regulated CD44s breast cancer xenograft model.

201 inistration of Onc.Ad in an HER2(+) prostate cancer xenograft model.

202 when intratumorally injected into a prostate cancer xenograft model.

203 h castration in a hormone-sensitive prostate cancer xenograft model.

204 efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.

205 ere, we examined this question in an ovarian cancer xenograft model.

206 r activity against the MIA PaCa-2 pancreatic cancer xenograft model.

207 g, motility, and tumor formation in a breast cancer xenograft model; however, its mechanism of action

208 curative efficacy in human melanoma and lung cancer xenograft models and are promising candidates for

209 of invasion in orthotopic breast and ovarian cancer xenograft models and obtained evidence that PI103

210 in human prostate (PC-3) and melanoma (A375) cancer xenograft models demonstrated that SMART-H and SM

211 ession levels of uPAR across different human cancer xenograft models in mice and to illustrate the cl

212 bute to cancer progression in human prostate cancer xenograft models in mice following castration.

213 ukemia and MDA-MB-231 triple-negative breast cancer xenograft models in mice.

214 f radiation therapy and intetumumab in human cancer xenograft models in nude rats to assess effects o

215 es tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung can

216 nificant antitumor effects in multiple human cancer xenograft models led to the selection of 28g (MPC

217 luminescence and NIR fluorescence imaging of cancer xenograft models represents a powerful in vivo st

218 itatively measured in vivo in human prostate cancer xenograft models through PET imaging with a fully

219 noninvasively detect active uPA in prostate cancer xenograft models using optical and single-photon

220 For in vivo PET studies, two human lung cancer xenograft models were established using MET-posit

221 hese effects were confirmed in vivo in colon cancer xenograft models with demonstrations that IGF-I r

222 tumor growth delay in eight different human cancer xenograft models with various PI3K pathway abnorm

223 In two colorectal cancer xenograft models, displaying differential sensiti

224 In breast cancer xenograft models, replacement of endogenous ALDH1

225 sed metastasis in MDA-MB-231 and -435 breast cancer xenograft models.

226 alogs for PET of GRPR expression in prostate cancer xenograft models.

227 hemical findings are recapitulated in breast cancer xenograft models.

228 says, and in subcutaneous colon and melanoma cancers xenografts models, suggests that demycarosyl-3D-

229 Using endometrial cancer xenografts, modulation of EMP2 expression resulte

230 er cells and growth of HER2+ NCI-N87 gastric cancer xenografts more potently than LJM716 or BYL719 al

231 e-independent growth conditions and a breast cancer xenograft mouse model to assess the impact of nic

232 esulting in an in vivo active (HCT-116 colon cancer xenograft mouse model) anticancer agent.

233 Importantly, in a preclinical gastric cancer xenograft mouse model, drug co-treatments led to

234 In a GPA33-positive human colorectal cancer xenograft mouse model, we validated a SPECT/CT-ba

235 ial for systemic radiovirotherapy in a liver cancer xenograft mouse model.

236 emonstrated against a triple negative breast cancer xenograft mouse model.

237 died by using an orthotopic human pancreatic cancer xenograft mouse model.

238 ough a survival study in a human HT-29 colon cancer xenograft murine model.

239 -replenishment) was performed in human colon cancer xenografts (n = 38) by using a clinical US system

240 In mice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combinati

241 Pancreatic cancer xenografts (PANC-1) in nude mice were treated sys

242 sing two androgen-independent human prostate cancer xenografts, PC-3 and DU-145, showed that DZ-50 tr

243 d 12 treatment groups in trial on an ovarian cancer xenograft, reproducing current therapeutic option

244 tion trial of PP242 in patient-derived colon cancer xenografts, resistance to PP242-induced inhibitio

245 nockdown of TRIP6 in glioblastoma or ovarian cancer xenografts restores nuclear p27(KIP1) expression

246 s antiangiogenic effects in a human prostate cancer xenograft, restoring tumor-dependent vessel growt

247 selective delivery of radiotracers to human cancer xenografts, resulting in rapid, significantly imp

248 ly target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing m

249 E2A and DOTA chelation systems in a prostate cancer xenograft SCID (severely compromised immunodefici

250 y targets p5365-73 peptide-expressing breast cancer xenografts, significantly inhibiting tumor growth

251 er PET intensity in the center of the breast cancer xenografts than in the contralateral tissues at 2

252 or uptake in nude mice bearing HeLa cervical cancer xenografts than nontargeted nanoparticles followi

253 screening in vivo on a novel human prostate cancer xenograft that is androgen-independent and induce

254 k of transplantable patient-derived prostate cancer xenografts that capture the biologic and molecula

255 ort spontaneous metastasis of human prostate cancer xenografts that express high levels of galectin-4

256 ndrogen-independent (CWR22R) human prostatic cancer xenografts, the acute response of CWR22 tumors to

257 erating intratumoral hypoxia in human breast cancer xenografts, the antiangiogenic agents sunitinib a

258 in vitro and its inhibition of s.c. prostate cancer xenografts, the Hsp90 inhibitor 17-AAG stimulates

259 was found (R(2) = 0.73; P < 0.0001) across 3 cancer xenografts, thus providing a strong argument for

260 trix transducer to monitor response of colon cancer xenografts to antiangiogenic therapy with functio

261 the muscle of mice-bearing human pancreatic cancer xenografts to provide noninvasive live imaging of

262 sensitized lung cancer cells and human lung cancer xenografts to radiotherapy and significantly prol

263 y and the therapeutic response of pancreatic cancer xenografts treated with a vaccinia virus carrying

264 homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in pro

265 rofiles in a set of patient-derived prostate cancer xenograft tumor lines, we identified miR-100-5p a

266 ion of tumor angiogenesis in a human ovarian cancer xenograft tumor model in mice.

267 served similar synergistic effects in a lung cancer xenograft tumor model.

268 colon, NCI-H292 lung, and BXPC-3 pancreatic cancer xenograft tumor models, IMC-41A10 inhibited tumor

269 n contrast, DIM did not protect human breast cancer xenograft tumors against radiation under the cond

270 levels retard, the growth of human prostate cancer xenograft tumors in mice.

271 y of fractionated radiation therapy in human cancer xenograft tumors in nude rats without increased t

272 Moreover, the volumes of prostate cancer xenograft tumors with knockdown of hCtr1 (179 +/-

273 knockdown reduces growth of lung and breast cancer xenograft tumors.

274 n adenovirus (AdTSTA-ELK1)-injected prostate cancer xenograft tumors.

275 vivo to mice bearing MDA-MB-468 human breast cancer xenografted tumors, these agents result in pharma

276 related peptidase 2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either m

277 ide imaging of IGF-1R expression in prostate cancer xenografts using a small nonimmunoglobulin-derive

278 vivo targeting of IGF-1R-expressing prostate cancer xenografts using an Affibody molecule.

279 excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR s

280 Pa, the amount of nanoparticles deposited in cancer xenografts was increased from 4- to 14-fold, and

281 in NSG mice harboring orthotopic pancreatic cancer xenografts, we assessed CSC viability, CSC freque

282 In mice bearing human breast cancer xenografts, we examined the biodistribution of (1

283 of glioblastoma tissue samples and prostate cancer xenografts, we identified a molecular signature f

284 e the effects of EF24 in vivo, HCT-116 colon cancer xenografts were established in nude mice and EF24

285 Finally, orthotopic breast cancer xenografts were established in nude mice by injec

286 bearing established Capan-1 human pancreatic cancer xenografts were given TF10 and then received the

287 SCID mice with human HCT116 cancer xenografts were imaged with (99m)Tc-TCP-1 or cont

288 Mice bearing subcutaneous prostate cancer xenografts were injected with 0.74-18.5 MBq of th

289 d Methods Twenty-three mice with human colon cancer xenografts were randomized to receive either sing

290 Athymic mice bearing human prostate cancer xenografts were subjected to 64Cu PET, followed b

291 e bearing subcutaneously implanted H460 lung cancer xenografts were treated with a novel vascular dis

292 In SKOV-3ip1 ovarian cancer xenografts, which express high levels of alpha(5)

293 st human androgen receptor-negative prostate cancer xenografts whose cells induced an osteoblastic re

294 Treatment of mice bearing a colon cancer xenograft with the antibiotic metronidazole reduc

295 Treatment of primary colorectal cancer xenografts with a small-molecule BMI-1 inhibitor

296 Pretreatment of mice bearing prostate cancer xenografts with acriflavine prevented tumor growt

297 nude mice bearing subcutaneous human breast cancer xenografts with different levels of HER2 expressi

298 Human prostate cancer xenografts with increased (64)Cu radioactivity we

299 the response to trastuzumab in BT474 breast cancer xenografts with N-[2-(4-(18)F-fluorobenzamido)eth

300 Treatment of mice bearing breast cancer xenografts with the inhibitory antibodies resulte